Xaluprine ®

Xaluprine® (Mercaptopurine 20mg/ml oral suspension) belongs to a group of medicines called cytotoxics also called chemotherapy). Cytotoxics work by stopping cancer cells from multiplying. Xaluprine is indicated for the treatment of acute lymphoblastic leukaemia in adults, adolescents and children.


Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia (ALL) is a type of cancer of Irie blood and bone marrow ... the spongy tissue inside bones wrere blood cells are made.

The word "acute" in acute lymphoblastic leukemia comes from the fact that the disease progresses rapidly and creates immature blood cells, rather than mature ones. The "lymphoblastic" in acute lymphoblastic leukemia refers to the white blood cells called lymphocytes, which ALL affects. Acute lymphoblastic leukemia is also known as acute lymphocytic leukemia.

Acute lymphoblastic leukemia is the most common type of cancer in children, and treatments result in a good chance for a cure.

Xromi® (Hydroxycarbamide 100mg/ml oral solution) is a medicine used in adults, adolescents and children over two years of age who have sickle cell disease, a genetic disease where the red blood cells becomerigid and sticky, and change from being disc-shaped to a crescent or sickle shape.

Hydroxycarbamide

Hydroxycarbamide is a medicine that is taken orally. It causes changes in the blood to reduce the frequency of sickle cell crises and the need for blood transfusions in patients with sickle cell disease. 3 It is also sometimes known as hydroxyurea 1

The importance of early initiation in sickle cell disease

It is recommended that all children over the age of 2 years with sickle cell disease are considered for treatment with hydroxycarbamide due to its impact of reducing the complications of the disease 1

Early initiation of hydroxycarbamide leads to sustained haematologic benefits and disease modification 1
Reduced incidence of pain crises and hospitalisation 1
Fewer acute chest syndrome events 1,2
Better spleen function 1,3,4
Improved growth 2
Possible preserved organ function in children 1,2
Stroke is a devastating complication of sickle cell anaemia with a high recurrence rate, in both children and adults, if left untreated 5

1. Qureshi A, et al. 2018. Br J Haematol
2. Hankins JS, et al. 2015. Am J. Hematol
3. Hankins JS, et al. 2005. Blood J.
4. Wang WC, et al. 2001. J Pediatr
5. Ware RE, et al. 2016. The Lancet

Further Information

The Summary of Product Characteristics and the Patient Information Leaflet (PIL), can be found on the eMC website.

For non-healthcare professionals please consult your Doctor or Nurse directly if you have any questions or concerns.

Alternatively you can view the Macmillan Cancer Support website and find out more about ALL or childhood ALL.

Adverse Effects

Please consult the Patient Information Leaflet (PIL) for a full list of side effects associated with the use of Xaluprine®.
Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Nova Laboratories Ltd, Martin House, Gloucester Crescent, Wigston, Leicester LE18 4YL
Email: [email protected]

The Xaluprine Team

> Karen Cole
Group Sales and Marketing Manager
Karen is primarily responsible for Nova’s licensed products but also oversees Nova’s ‘Specials’ portfolio both in the UK and Internationally.

For Sales and Marketing enquiries please contact Karen at [email protected]

Xromi ®

Xromi® (Hydroxycarbamide 100mg/ml oral solution) is a medicine used in adults, adolescents and children over two years of age who have sickle cell disease, a genetic disease where the red blood cells becomerigid and sticky, and change from being disc-shaped to a crescent or sickle shape.

Hydroxycarbamide

Hydroxycarbamide is a medicine that is taken orally. It causes changes in the blood to reduce the frequency of sickle cell crises and the need for blood transfusions in patients with sickle cell disease. (3) It is also sometimes known as hydroxyurea (1)

The importance of early initiation in sickle cell disease

It is recommended that all children over the age of 2 years with sickle cell disease are considered for treatment with hydroxycarbamide due to its impact of reducing the complications of the disease 1

Early initiation of hydroxycarbamide leads to sustained haematologic benefits and disease modification 1
Reduced incidence of pain crises and hospitalisation 1
Fewer acute chest syndrome events 1,2
Better spleen function 1,3,4
Improved growth 2
Possible preserved organ function in children 1,2
Stroke is a devastating complication of sickle cell anaemia with a high recurrence rate, in both children and adults, if left untreated 5

1. Qureshi A, et al. 2018. Br J Haematol
2. Hankins JS, et al. 2015. Am J. Hematol
3. Hankins JS, et al. 2005. Blood J.
4. Wang WC, et al. 2001. J Pediatr
5. Ware RE, et al. 2016. The Lancet


supersickle.com

Please contact Nova at [email protected] to obtain the password to access the site.

Please visit supersickle.com where we have created a range of engaging and informative resources to help joint decision-making between healthcare providers, parents and the patient








Further Information

The Summary of Product Characteristics and the Patient Information Leaflet (PIL), can be found on the eMC website.

For non-healthcare professionals please consult your Doctor or Nurse directly if you have any questions or concerns.

Alternatively you can obtain more information on Sickle Cell Disease via the Sickle Cell Society website sicklecellsociety.org

Adverse Effects

Please consult the Patient Information Leaflet (PIL) for a full list of side effects associated with the use of Xromi®.
Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Nova Laboratories Ltd, Martin House, Gloucester Crescent, Wigston, Leicester LE18 4YL
Email: [email protected]

The Xromi Team

For Sales and Marketing Enquiries please contact Karen Cole, Group Sales and Marketing Manager at:
[email protected]

Disclaimer - Third party and links to external websites

If you are leaving the Nova Laboratories website via a link to a third party website, please note that the accuracy and content of any such website is not the responsibility of Nova Laboratories Ltd.

The Xromi Team

For Sales and Marketing Enquiries please contact Karen Cole, Group Sales and Marketing Manager at:
[email protected]

Careers

We welcome speculative enquiries and appl1cat1ons from anyone with experience In the pharmaceutical industry, the right attitude and relevant qualifications.

Contact Us

For all product enquires, please contact our customer services team on 0800 975 48 40 or alternatively you can email us at [email protected]
Our Other Services